Author:
Zelniker Thomas A,Wiviott Stephen D,Raz Itamar,Im Kyungah,Goodrich Erica L,Bonaca Marc P,Mosenzon Ofri,Kato Eri T,Cahn Avivit,Furtado Remo H M,Bhatt Deepak L,Leiter Lawrence A,McGuire Darren K,Wilding John P H,Sabatine Marc S
Reference39 articles.
1. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes;Zinman;N Engl J Med,2015
2. Canagliflozin and cardiovascular and renal events in type 2 diabetes;Neal;N Engl J Med,2017
3. Dapagliflozin and cardiovascular outcomes in type 2 diabetes;Wiviott;N Engl J Med,2018
4. Guidance for industry: diabetes mellitus evaluating cardiovascular risk in new antidiabetic therapies to treat type 2 diabetes,2008
5. 2016 European Guidelines on cardiovascular disease prevention in clinical practice
Cited by
1938 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献